Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$3.34 - $4.29 $58,917 - $75,675
17,640 New
17,640 $64,000
Q4 2022

Feb 14, 2023

BUY
$3.02 - $5.37 $6,970 - $12,393
2,308 Added 22.02%
12,789 $67,000
Q3 2022

Nov 14, 2022

SELL
$2.99 - $4.35 $39,811 - $57,920
-13,315 Reduced 55.95%
10,481 $32,000
Q2 2022

Aug 15, 2022

BUY
$2.67 - $4.77 $29,054 - $51,907
10,882 Added 84.27%
23,796 $91,000
Q1 2022

May 16, 2022

BUY
$2.62 - $4.45 $33,834 - $57,467
12,914 New
12,914 $48,000
Q4 2021

Feb 14, 2022

SELL
$4.05 - $5.37 $162,708 - $215,739
-40,175 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$3.89 - $5.48 $90,360 - $127,294
23,229 Added 137.08%
40,175 $175,000
Q2 2021

Aug 16, 2021

BUY
$3.61 - $5.45 $14,281 - $21,560
3,956 Added 30.45%
16,946 $92,000
Q1 2021

May 17, 2021

BUY
$3.14 - $6.14 $40,788 - $79,758
12,990 New
12,990 $51,000
Q3 2020

Nov 16, 2020

SELL
$1.56 - $2.08 $45,606 - $60,808
-29,235 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$0.94 - $2.21 $729 - $1,714
776 Added 2.73%
29,235 $51,000
Q1 2020

May 15, 2020

SELL
$0.84 - $1.76 $685 - $1,436
-816 Reduced 2.79%
28,459 $29,000
Q4 2019

Feb 14, 2020

BUY
$1.14 - $1.49 $19,097 - $24,960
16,752 Added 133.77%
29,275 $38,000
Q3 2019

Nov 14, 2019

SELL
$1.04 - $1.44 $25,021 - $34,644
-24,059 Reduced 65.77%
12,523 $16,000
Q2 2019

Aug 14, 2019

SELL
$1.09 - $1.88 $12,493 - $21,548
-11,462 Reduced 23.86%
36,582 $42,000
Q1 2019

May 15, 2019

BUY
$1.14 - $2.25 $54,770 - $108,099
48,044 New
48,044 $95,000
Q3 2018

Nov 14, 2018

SELL
$1.01 - $2.19 $22,654 - $49,121
-22,430 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$1.59 - $2.38 $370 - $554
-233 Reduced 1.03%
22,430 $43,000
Q1 2018

May 15, 2018

SELL
$2.28 - $3.8 $6,956 - $11,593
-3,051 Reduced 11.87%
22,663 $52,000
Q4 2017

Feb 14, 2018

BUY
$2.28 - $6.71 $58,627 - $172,540
25,714
25,714 $60,000

Others Institutions Holding MNKD

About MANNKIND CORP


  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $1.44B
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track This Portfolio

Track Two Sigma Securities, LLC Portfolio

Follow Two Sigma Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Securities, LLC with notifications on news.